Patents Issued in October 11, 2016
-
Patent number: 9463164Abstract: The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. A film-coated tablet obtained by mixing granulated particles obtained by granulating a mixture containing (a) the aforementioned active component, (b) one or more kinds of fillers selected from lactose, D-mannitol, erythritol and crystalline cellulose, (c) a cellulose-based disintegrant and (d) a water-soluble binder with a later powder containing (e) one or more kinds of fillers selected from lactose, D-mannitol and crystalline cellulose and/or (f) a cellulose-based disintegrant, forming the mixture, and applying film coating.Type: GrantFiled: January 22, 2014Date of Patent: October 11, 2016Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Makiko Yanagida, Hiroyuki Nishii, Masayuki Nakazono
-
Patent number: 9463165Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises at least one kind of water soluble polymer and tannic acid allows production of tablets that can be produced by a simple process with simple production equipment, disintegrate fast in the mouth, and have a proper level of moldability for practical use. The at least one kind of water soluble polymer is preferably selected from the group consisting of povidone, hydroxypropyl cellulose, pullulan, a polyvinyl alcohol-polyethylene glycol graft copolymer and copolyvidone.Type: GrantFiled: September 4, 2013Date of Patent: October 11, 2016Assignee: TEIKA PHARMACEUTICAL CO., LTD.Inventors: Takao Shimatani, Takahiro Kawagishi
-
Patent number: 9463166Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.Type: GrantFiled: February 8, 2016Date of Patent: October 11, 2016Assignee: Recro Gainesville LLCInventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
-
Patent number: 9463167Abstract: Disclosed is a composition comprising MZ for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject.Type: GrantFiled: February 10, 2015Date of Patent: October 11, 2016Assignee: Howard Foundation Holdings LimitedInventors: John Nolan, Stephen Beatty, James Loughman, Alan N. Howard, David Thurnham
-
Patent number: 9463168Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.Type: GrantFiled: June 2, 2015Date of Patent: October 11, 2016Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), AURIS MEDICAL AGInventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
-
Patent number: 9463169Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.Type: GrantFiled: August 17, 2012Date of Patent: October 11, 2016Assignee: MicroBiome Therapeutics, LLCInventors: Mark L. Heiman, Dean P. Stull, Justin W. Peno
-
Patent number: 9463170Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.Type: GrantFiled: June 8, 2015Date of Patent: October 11, 2016Assignee: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Nigel R. A. Beeley, Mark S. Fineman
-
Patent number: 9463171Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.Type: GrantFiled: January 9, 2013Date of Patent: October 11, 2016Assignee: Welichem Biotech Inc.Inventors: Claudiu Supuran, Shoukat Dedhar, Paul C. McDonald, Fabrizio Carta
-
Patent number: 9463172Abstract: The present invention is directed to a method of treating a subject with autism spectrum disorder by administering an acetylaminopropane sulfonate.Type: GrantFiled: February 12, 2010Date of Patent: October 11, 2016Assignee: Indiana University Research & Technology CorporationInventor: Craig A. Erickson
-
Patent number: 9463173Abstract: The present invention relates to the field of obesity. More specifically, the present invention provides methods and compositions useful in treating obesity and obesity-associated conditions. In one embodiment, a method for treating obesity in a subject comprises the step of administering an effective amount of valproic acid (VPA) or an analog, derivative or metabolite thereof to the subject.Type: GrantFiled: March 4, 2015Date of Patent: October 11, 2016Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Namandje Bumpus, Lindsay Avery
-
Patent number: 9463174Abstract: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.Type: GrantFiled: March 24, 2014Date of Patent: October 11, 2016Inventor: Qinghua Wang
-
Patent number: 9463175Abstract: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.Type: GrantFiled: June 22, 2015Date of Patent: October 11, 2016Assignees: SBI Pharmaceuticals Co., Ltd., The University of TokyoInventors: Tohru Tanaka, Satofumi Kawata, Takeo Kohda, Motowo Nakajima, Kiyoshi Kita
-
Patent number: 9463176Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: GrantFiled: November 11, 2011Date of Patent: October 11, 2016Assignee: N.V. NutriciaInventor: Robert J. J. Hageman
-
Patent number: 9463177Abstract: Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that find use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions find use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g.Type: GrantFiled: September 9, 2013Date of Patent: October 11, 2016Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.Inventors: Michael S. Conte, Charles N. Serhan, Tejal A. Desai
-
Patent number: 9463178Abstract: An ophthalmic solution is provided. The ophthalmic solution includes an ultraviolet-A absorber and an ultraviolet-B absorber. The ophthalmic solution has a viscosity of between about 1 and 100 cps. The ophthalmic solution can be used to absorb ultraviolet radiation in the eye.Type: GrantFiled: July 27, 2015Date of Patent: October 11, 2016Inventor: Brian J. Smith
-
Patent number: 9463179Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.Type: GrantFiled: November 23, 2015Date of Patent: October 11, 2016Assignee: Milestone Pharmaceuticals Inc.Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
-
Patent number: 9463180Abstract: Methods for treating molluscum contagiosum warts include identifying a human with one or more molluscum contagiosum warts and applying an anti-infective composition to the one or more warts. The anti-infective composition comprises at least one anti-infective agent in a liquid carrier, such as an organohalide. The liquid carrier includes a tissue penetrating component for rapid penetration of the anti-infective agent into the one or more molluscum contagiosum warts. Application of the anti-infective composition to molluscum contagiosum warts causes the warts to turn black and/or fall off the skin in less than about 5 days.Type: GrantFiled: March 14, 2014Date of Patent: October 11, 2016Assignee: QUADEX PHARMACEUTICALS, LLCInventor: B. Ron Johnson
-
Patent number: 9463181Abstract: The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.Type: GrantFiled: December 3, 2012Date of Patent: October 11, 2016Assignees: Pemix Sleep, Inc., ProCom One, Inc.Inventors: Susan E. Dubé, Neil B. Kavey
-
Patent number: 9463182Abstract: The use, as a dermatological or cosmetic ingredient, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization in situ.Type: GrantFiled: November 7, 2014Date of Patent: October 11, 2016Assignee: THESAN PHARMACEUTICALS, INC.Inventor: Jean Hilaire Saurat
-
Patent number: 9463183Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.Type: GrantFiled: November 6, 2015Date of Patent: October 11, 2016Assignee: SILVERGATE PHARMACEUTICALS, INC.Inventors: Gerold L. Mosher, David W. Miles
-
Patent number: 9463184Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.Type: GrantFiled: November 13, 2013Date of Patent: October 11, 2016Assignee: Nant Holdings IP, LLCInventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
-
Patent number: 9463185Abstract: A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.Type: GrantFiled: June 27, 2014Date of Patent: October 11, 2016Assignees: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
-
Patent number: 9463186Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).Type: GrantFiled: April 15, 2014Date of Patent: October 11, 2016Assignee: Northwestern UniversityInventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
-
Patent number: 9463187Abstract: The present invention provides methods of using compounds of formula I: and salts and prodrugs thereof, wherein n, R1 and R2 are defined herein. The invention also provides certain novel compounds of formula I and pharmaceutical compositions comprising them.Type: GrantFiled: November 3, 2011Date of Patent: October 11, 2016Assignee: Ampio Pharmaceuticals, Inc.Inventors: David Bar-Or, Nagaraja K. R. Rao
-
Patent number: 9463188Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.Type: GrantFiled: November 26, 2013Date of Patent: October 11, 2016Assignees: TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Haruhisa Kikuchi, Yoshiteru Oshima, Toshio Hattori, Yuzuru Kubohara, Osamu Yamada, Jing Zhang, Yoshihisa Matsushita, Shinya Kida
-
Patent number: 9463189Abstract: Disclosed herein are new methods of treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver in a subject by modulating PPAR? with sulfonyl-substituted bicyclic compounds and compositions as pharmaceuticals.Type: GrantFiled: May 14, 2013Date of Patent: October 11, 2016Assignee: BPV Holdings, LLCInventors: Mausumee Guha, Paul Grint
-
Patent number: 9463190Abstract: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.Type: GrantFiled: March 31, 2009Date of Patent: October 11, 2016Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Theresa A. Zesiewicz, Kelly L. Sullivan
-
Patent number: 9463191Abstract: A composition of an antitussive, a decongestant, or an antihistamine to treat upper respiratory and oral pharyngeal congestion and related symptoms in a patient.Type: GrantFiled: June 8, 2015Date of Patent: October 11, 2016Assignee: GM Pharmaceuticals, Inc.Inventor: Odes W. Mitchell
-
Patent number: 9463192Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.Type: GrantFiled: February 18, 2014Date of Patent: October 11, 2016Assignee: ONO PHARMACEUTICAL CO., LTD.Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura
-
Patent number: 9463193Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.Type: GrantFiled: September 26, 2008Date of Patent: October 11, 2016Assignees: INSTITUT DE CANCEROLOGIE DE L'OUEST, UNIVERSITE D'ANGERSInventors: Erick Gamelin, Michéle Boisdron-Celle, Alain Morel
-
Patent number: 9463194Abstract: The disclosure describes methods for treatment of patients co-infected with HIV and tuberculosis, wherein the patient receives effective amounts of elvitegravir, an antimycobacterial agent and a CYP inhibitor.Type: GrantFiled: February 4, 2015Date of Patent: October 11, 2016Assignee: Gilead Sciences, Inc.Inventors: Rebecca Restituto Begley, Joseph Marcello Custodio, Brian P. Kearney
-
Patent number: 9463195Abstract: Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a ?-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the ?-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of an animal. It also relates to methods for determining which compounds are effective at disrupting amyloid fibrils in a medium.Type: GrantFiled: December 14, 2007Date of Patent: October 11, 2016Assignee: The Regents of the University of CaliforniaInventors: David S. Eisenberg, Melinda Balbirnie
-
Patent number: 9463196Abstract: The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided.Type: GrantFiled: August 7, 2015Date of Patent: October 11, 2016Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Ravish Kumar Sharma, Pulak Kumar Metia, Ravinder Singh, Rajesh Srikrishan Shear, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh, Swarna Pappu, Prabhakar Konatham, Pruthvipathy Katikaneni, Dileep Jami
-
Patent number: 9463197Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.Type: GrantFiled: July 15, 2014Date of Patent: October 11, 2016Assignee: NATIONAL TAIWAN NORMAL UNIVERSITYInventors: Guey-Jen Lee-Chen, Hsiu-Mei Hsieh, Guan-Chiun Lee
-
Patent number: 9463198Abstract: Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.Type: GrantFiled: April 18, 2014Date of Patent: October 11, 2016Assignee: Infectious Disease Research InstituteInventors: Shamgar Ben-Eliyahu, Pini Matzner, Steven G. Reed
-
Patent number: 9463199Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.Type: GrantFiled: March 23, 2005Date of Patent: October 11, 2016Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
-
Patent number: 9463200Abstract: The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2? position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R1, R2, R3, R4, p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.Type: GrantFiled: February 28, 2014Date of Patent: October 11, 2016Assignee: OLIGOMER SCIENCES ABInventors: Roger Strömberg, Dmytro Honcharenko, Stefan Milton
-
Patent number: 9463201Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.Type: GrantFiled: June 5, 2015Date of Patent: October 11, 2016Assignee: M.G. THERAPEUTICS LTDInventors: Yair Alster, Omer Rafaeli, K. Angela Macfarlane, Cary Reich, Shimon Amselem, Doron Friedman
-
Patent number: 9463202Abstract: A dialysis acid precursor assembly including a dialysis acid precursor composition of dry components including anhydrous glucose, a dry acid, a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O) and a potassium salt or calcium salt, and a moisture-resistant container with a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dialysis acid precursor composition is sealed within the container.Type: GrantFiled: December 11, 2012Date of Patent: October 11, 2016Assignee: Gambro Lundia ABInventors: Olof Jansson, Jens Gustafsson, Torbjorn Linden
-
Patent number: 9463203Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.Type: GrantFiled: August 18, 2014Date of Patent: October 11, 2016Assignee: Cytori Therapeutics, Inc.Inventors: Marc H. Hedrick, John K. Fraser, Susan L. Riley, Ronda E. Schreiber
-
Patent number: 9463204Abstract: The object of the invention is to provide a technique of suppressing tumorigenesis in IPS cells and inducing differentiation into target differentiated cells. In use of a statin and a differentiation inducer, iPS cells are differentiated into target differentiated cells, whereby iPS cells can be differentiated into differentiated cells in which tumorigenesis is suppressed.Type: GrantFiled: December 27, 2012Date of Patent: October 11, 2016Assignee: Osaka UniversityInventor: Hiroshi Egusa
-
Patent number: 9463205Abstract: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.Type: GrantFiled: October 15, 2014Date of Patent: October 11, 2016Assignee: BioCrine ABInventors: Per-Olof Berggren, Alejandro Caicedo
-
Patent number: 9463206Abstract: Described herein are tissue grafts produced by contacting dehydrated placental tissue grafts with a cross-linking agent. The tissue grafts described herein provide barrier and prevent the migration of a bioactive agent from the wound. Thus, the tissue grafts enhance wound healing while preventing the undesirable migration of a bioactive agent from the wound. Methods for making and using the cross-linked grafts are also described herein.Type: GrantFiled: December 18, 2012Date of Patent: October 11, 2016Assignee: MiMedx Group, Inc.Inventors: Tom Koob, John Daniel, Randall Spencer
-
Patent number: 9463207Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.Type: GrantFiled: May 22, 2014Date of Patent: October 11, 2016Assignee: MiMedx Group, Inc.Inventor: John Daniel
-
Patent number: 9463208Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.Type: GrantFiled: December 2, 2013Date of Patent: October 11, 2016Assignee: REBIOTIX, INC.Inventor: Edwin J. Hlavka
-
Patent number: 9463209Abstract: The present invention relates to an extract from bacterial strains, such as Staphylococcus, Moraxella, Klebsiella, Streptococcus, and Haemophilus. The extract is useful as a treatment for indications such as respiratory disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.Type: GrantFiled: March 20, 2014Date of Patent: October 11, 2016Assignee: OM PHARMA SAInventors: Jacques Alain Bauer, Marco Salvagni, Jean-Pierre Leon Vigroux, Laetitia Chalvet, Carlo Chiavaroli
-
Patent number: 9463210Abstract: A method for alleviating cravings and discomfort of a user due to nicotine addiction upon immediate cessation of tobacco by said user, comprising the steps of inhaling, upon commencement of a nicotine craving episode, for about 10 minutes, between about 3 to 5 drops of rosemary essential oil, wherein said rosemary essential oil is sprinkled on an apposite vaporizer pad, orally ingesting between about 250 mg to 500 mg of niacinamide, orally ingesting between about 200 mg to 300 mg of sarcosine, orally ingesting between about 300 mg to 600 mg of red Korean ginseng extract, and orally ingesting about 500 mg of soy lecithin.Type: GrantFiled: October 7, 2015Date of Patent: October 11, 2016Inventor: Antonino Cavallaro
-
Patent number: 9463211Abstract: The subject patent discloses a method for treating intertrigo on the underside of a female breasts which comprises (1) applying a skin salve to the underside of the female breasts, wherein the female breasts are dry, and wherein the skin salve is comprised of (i) petrolatum, (ii) from 11 weight percent to 60 weight percent beeswax, and (iii) from 0.25 weight percent to 10 weight percent peppermint oil, wherein the skin salve has a viscosity at 25° C. which is within the range of 11 Pa·s to 15 Pa·s at a shear rate of 35 l/s, and (2) allowing the skin salve to remain in contact with female breasts for a period of at least 4 hours.Type: GrantFiled: November 10, 2015Date of Patent: October 11, 2016Inventor: Teresa D. Carter
-
Patent number: 9463212Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil, coconut oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; aloe vera; and a preservative, such as benzalkonium chloride and vitamin E.Type: GrantFiled: April 2, 2015Date of Patent: October 11, 2016Assignee: GLOBAL LIFE TECHNOLOGIES CORP.Inventor: John A. Willimann
-
Patent number: 9463213Abstract: The use of degarelix in the treatment of endometriosis, in particular in the treatment of endometriotic ovarian cysts and recurrent endometriotic lesions following surgery and in the treatment of endometriosis and/or endometriotic ovarian cysts in patients who plan to undergo assisted reproduction, is described, wherein this treatment is performed before the patients are subjected to assisted reproduction; degarelix is administered for this purpose as a single dose of 80-120 mg, preferably 80 mg, subcutaneously.Type: GrantFiled: September 25, 2013Date of Patent: October 11, 2016Inventors: Fabio Scarpellini, Marco Sbracia